Following Europe, China grants Patent for GeneQuine’s Lead Products

Chinese Patent Office grants Patent for GeneQuine’s Lead Products.

The patent covers helper-dependent adenoviral vectors expressing interleukin-1 receptor antagonist and their use in the treatment of osteoarthritis. China is one of the largest and fastest growing markets for osteoarthritis in Asia. Securing intellectual protection represents a major milestone in this target market. Patent applications for this technology are pending in other regions of the world.